Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 186HER2-positive Breast Cancer 18Neoplasm Metastasis 6Inflammatory Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasms 4Prostatic Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3HER2-positive Early Breast Cancer 3Endometrial Neoplasms 3Breast Neoplasms, Male 3Anatomic Stage I Breast Cancer AJCC v8 3Stomach Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Locally Advanced Breast Cancer 2Hematologic Neoplasms 2HER2-positive Metastatic Breast Cancer 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Breast Diseases 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1

Interventions

Fulvestrant 3palbociclib 2Letrozole 2Anastrozole 2venetoclax 1pyrotinib 1pertuzumab 1penpulimab 1dalpiciclib 1anlotinib 1Tretinoin 1Trastuzumab 1Ropivacaine 1Radiosurgery 1Propofol 1Patient Reported Outcome Measures 1Paclitaxel 1Ondansetron 1Morphine 1Induction Chemotherapy 1Etoricoxib 1Docetaxel 1Diagnostic Imaging 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasm Female × pertuzumab × Breast × Clear all
NCT05969184 2023-08-01

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Peking University Cancer Hospital & Institute

Phase 2 Unknown
94 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡